ENG/中
老虎证券
行情
交易
收费
下载
优惠与活动
帮助
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
股权激励
关于
登录
立即注册
Toggle
澳股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
IMMUTEP LTD
0.385
-0.005
-1.28%
成交量：
244.14万
成交额：
94.70万
市值：
5.67亿
市盈率：
-9.12
高：
0.395
开：
0.385
低：
0.370
收：
0.390
52周最高：
0.470
52周最低：
0.222
股本：
14.74亿
流通股本：
12.28亿
量比：
0.88
换手率：
0.20%
股息：
- -
股息率：
- -
每股收益(TTM):
-0.042
每股收益(LYR):
-0.042
净资产收益率：
-36.88%
总资产收益率：
-22.66%
市净率：
3.95
市盈率(LYR):
-9.12
数据加载中...
总览
公司
新闻资讯
公告
IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果
美股速递
·
2025/12/22
Immutep与Dr. Reddy's达成战略合作 推广创新肿瘤药物Eftilagimod Alfa
投资观察
·
2025/12/08
IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利
美股速递
·
2025/12/08
IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa
美股速递
·
2025/12/08
IMMUTEP LTD - 有资格获得高达3.495亿美元的潜在监管开发和商业里程碑付款
美股速递
·
2025/12/08
在2025年ESMO大会上，Eftisarc-Neo II期试验显示Efti在软组织肉瘤新辅助治疗中的主要终点达成
美股速递
·
2025/10/20
IMMUTEP LTD宣布一线非小细胞肺癌Tacti-004（Keynote-F91）III期试验最新进展
美股速递
·
2025/10/09
Immutep宣布与乔治华盛顿大学癌症中心开展研究合作，评估新辅助治疗药物Efti
美股速递
·
2025/09/22
Immutep宣布Eftisarc-Neo II期试验数据获CTOS 2025大会口头报告接受 该试验评估Efti在软组织肉瘤中的新辅助疗法
美股速递
·
2025/09/08
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/IMM.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.385,"timestamp":1771909920000,"preClose":0.39,"halted":0,"volume":2441417,"delay":0,"changeRate":-0.012820512820512832,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.042199,"marketStatus":"未开盘","change":-0.005,"latestTime":"02-24 16:12:00 AEDT","open":0.385,"high":0.395,"low":0.37,"amount":947003,"amplitude":0.064103,"askPrice":0.39,"askSize":25000,"bidPrice":0.37,"bidSize":77369,"shortable":3,"etf":0,"ttmEps":-0.042199,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1771974000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.39,"openAndCloseTimeList":[[1771887600000,1771909200000]],"volumeRatio":0.882417,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-22.66%","roe":"-36.88%","lyrEps":-0.042199,"volumeRatio":0.882417,"shares":1473721306,"dividePrice":0,"high":0.395,"amplitude":0.064103,"preClose":0.39,"low":0.37,"week52Low":0.222,"pbRate":"3.95","psRate":"112.49","week52High":0.47,"institutionHeld":0,"latestPrice":0.385,"committee":0.511571,"eps":-0.042199,"divideRate":0,"volume":2441417,"delay":0,"ttmEps":-0.042199,"open":0.385,"prevYearClose":0.415,"prevWeekClose":0.395,"prevMonthClose":0.395,"prevQuarterClose":0.415,"fiveDayClose":0.385,"twentyDayClose":0.44,"sixtyDayClose":0.27,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1132253135","title":"IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1132253135","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132253135?lang=zh_cn&edition=fundamental","pubTime":"2025-12-22 21:02","pubTimestamp":1766408522,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"1173503970","title":"Immutep与Dr. Reddy's达成战略合作 推广创新肿瘤药物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1173503970","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173503970?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 21:18","pubTimestamp":1765199884,"startTime":"0","endTime":"0","summary":"12月8日 - Immutep Ltd宣布，Immutep与Dr. Reddy’s达成了战略合作协议，共同推广一种创新的肿瘤药物Eftilagimod Alfa。根据协议，Immutep将获得2,000万美元的预付款，以及最高可达3.495亿美元的额外资金。此外，Dr. Reddy's将获得在北美、欧洲、日本及大中华区以外所有国家对Eftilagimod Alfa的独家权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"1138437616","title":"IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1138437616","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138437616?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 21:09","pubTimestamp":1765199347,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1156951078","title":"IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1156951078","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156951078?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199131,"startTime":"0","endTime":"0","summary":"IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"1192332602","title":"IMMUTEP LTD - 有资格获得高达3.495亿美元的潜在监管开发和商业里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1192332602","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192332602?lang=zh_cn&edition=fundamental","pubTime":"2025-12-08 15:30","pubTimestamp":1765179011,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD - 有资格获得高达3.495亿美元的潜在监管开发和商业里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"1136653615","title":"在2025年ESMO大会上，Eftisarc-Neo II期试验显示Efti在软组织肉瘤新辅助治疗中的主要终点达成","url":"https://stock-news.laohu8.com/highlight/detail?id=1136653615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136653615?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 20:01","pubTimestamp":1760961701,"startTime":"0","endTime":"0","summary":"在2025年ESMO大会上，Eftisarc-Neo II期试验显示Efti在软组织肉瘤的新辅助治疗中的主要终点达成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1137674400","title":"IMMUTEP LTD宣布一线非小细胞肺癌Tacti-004（Keynote-F91）III期试验最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1137674400","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137674400?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 20:00","pubTimestamp":1760011230,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD宣布一线非小细胞肺癌Tacti-004（Keynote-F91）III期试验最新进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1124383017","title":"Immutep宣布与乔治华盛顿大学癌症中心开展研究合作，评估新辅助治疗药物Efti","url":"https://stock-news.laohu8.com/highlight/detail?id=1124383017","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124383017?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 20:02","pubTimestamp":1758542533,"startTime":"0","endTime":"0","summary":"Immutep宣布与乔治华盛顿大学癌症中心开展研究合作，评估新辅助治疗药物Efti","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"1158451855","title":"Immutep宣布Eftisarc-Neo II期试验数据获CTOS 2025大会口头报告接受 该试验评估Efti在软组织肉瘤中的新辅助疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1158451855","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158451855?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 20:01","pubTimestamp":1757332877,"startTime":"0","endTime":"0","summary":"Immutep宣布，其Eftisarc-Neo II期临床试验的数据已被CTOS 2025大会接受进行口头报告展示。该试验主要评估新辅助疗法Efti在软组织肉瘤治疗中的效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}